AZN.L vs BMY
AZN.L: A global biopharmaceutical leader specializing in high-impact therapeutic areas like oncology, rare diseases, and cardiovascular medicine. BMY: A leading biopharmaceutical innovator focused on discovering and delivering life-changing medicines to address serious illnesses globally.
Side-by-side fundamentals
| Metric | AZN.L | BMY | Edge |
|---|---|---|---|
| Price as of 2026-08-03 close | £115.00 | $63.63 | |
| Market cap as of 2026-08-06 | n/a | $130.0B | |
| P/E as of 2026-08-06 | n/a | 13.99 | |
| PEG as of 2026-08-06 | n/a | -8.67 | |
| Net margin as of 2026-08-06 | n/a | +18.9% | |
| Gross margin as of 2026-08-06 | n/a | +71.7% | |
| Operating margin as of 2026-08-06 | n/a | +25.5% | |
| ROE as of 2026-08-06 | n/a | +46.8% | |
| ROA as of 2026-08-06 | n/a | +10.3% | |
| Debt / equity as of 2026-08-06 | n/a | 1.93 | |
| Revenue growth (YoY) as of 2026-08-06 | n/a | +3.1% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +1.4% | |
| Dividend yield as of 2026-08-06 | n/a | +3.8% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-08-06 | n/a | 0.17 | |
| 1-year return as of 2026-08-03 close | +3.6% | +38.8% | BMY higher |
Fundamentals: market data, as of 2026-08-06. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-03.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.